| Attribute |
Value |
| 52 Week Change |
-0.48618782 |
| Address1 |
830 Winter Street |
| All Time High |
14.71 |
| All Time Low |
0.825 |
| Ask |
1.19 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
1,229,430 |
| Average Daily Volume3 Month |
808,280 |
| Average Volume |
808,280 |
| Average Volume10Days |
1,229,430 |
| Beta |
1.038 |
| Bid |
0.7416 |
| Bid Size |
2 |
| Book Value |
1.613 |
| City |
Waltham |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.93 |
| Current Ratio |
6.648 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
1.04 |
| Day Low |
0.9101 |
| Debt To Equity |
95.476 |
| Display Name |
TScan Therapeutics |
| Earnings Timestamp End |
1,762,954,200 |
| Earnings Timestamp Start |
1,762,954,200 |
| Ebitda |
-123,821,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.204 |
| Enterprise To Revenue |
2.764 |
| Enterprise Value |
25,256,260 |
| Eps Current Year |
-0.8425 |
| Eps Forward |
-0.8875 |
| Eps Trailing Twelve Months |
-0.96 |
| Esg Populated |
0 |
| Exchange |
NGM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.03318 |
| Fifty Day Average Change |
-0.10317999 |
| Fifty Day Average Change Percent |
-0.09986642 |
| Fifty Two Week Change Percent |
-48.618782 |
| Fifty Two Week High |
2.57 |
| Fifty Two Week High Change |
-1.6399999 |
| Fifty Two Week High Change Percent |
-0.6381323 |
| Fifty Two Week Low |
0.825 |
| Fifty Two Week Low Change |
0.10500002 |
| Fifty Two Week Low Change Percent |
0.12727275 |
| Fifty Two Week Range |
0.825 - 2.57 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,626,442,200,000 |
| Float Shares |
55,390,045 |
| Forward Eps |
-0.8875 |
| Forward P E |
-1.0478873 |
| Free Cashflow |
-84,107,624 |
| Full Exchange Name |
NasdaqGM |
| Full Time Employees |
138 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-95,530,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00196 |
| Held Percent Institutions |
0.59464 |
| Implied Shares Outstanding |
65,350,817 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-07-16 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. |
| Long Name |
TScan Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
60,776,260 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_583057578 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-124,305,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
60,779,526 |
| Number Of Analyst Opinions |
4 |
| Open |
1.04 |
| Operating Cashflow |
-122,012,000 |
| Operating Margins |
-29.67312 |
| Payout Ratio |
0.0 |
| Phone |
857 399 9500 |
| Pre Market Change |
0.0 |
| Pre Market Change Percent |
0.0 |
| Pre Market Price |
0.93 |
| Pre Market Time |
1,784,112,995 |
| Previous Close |
1.03 |
| Price Eps Current Year |
-1.1038576 |
| Price Hint |
4 |
| Price To Book |
0.5765654 |
| Price To Sales Trailing12 Months |
6.652393 |
| Profit Margins |
0.0 |
| Quick Ratio |
6.412 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.099999964 |
| Regular Market Change Percent |
-9.7087345 |
| Regular Market Day High |
1.04 |
| Regular Market Day Low |
0.9101 |
| Regular Market Day Range |
0.9101 - 1.04 |
| Regular Market Open |
1.04 |
| Regular Market Previous Close |
1.03 |
| Regular Market Price |
0.93 |
| Regular Market Time |
1,784,059,200 |
| Regular Market Volume |
1,640,085 |
| Return On Assets |
-0.2962 |
| Return On Equity |
-0.80947995 |
| Revenue Growth |
-0.548 |
| Revenue Per Share |
0.152 |
| Sand P52 Week Change |
0.2043345 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
61,074,229 |
| Shares Percent Shares Out |
0.0108 |
| Shares Short |
708,200 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
934,310 |
| Short Name |
TScan Therapeutics, Inc. |
| Short Percent Of Float |
0.015800001 |
| Short Ratio |
1.2 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
TCRX |
| Target High Price |
7.0 |
| Target Low Price |
5.0 |
| Target Mean Price |
6.0 |
| Target Median Price |
6.0 |
| Total Cash |
128,057,000 |
| Total Cash Per Share |
1.96 |
| Total Debt |
92,537,000 |
| Total Revenue |
9,136,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.96 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.203375 |
| Two Hundred Day Average Change |
-0.27337497 |
| Two Hundred Day Average Change Percent |
-0.22717355 |
| Type Disp |
Equity |
| Volume |
1,640,085 |
| Website |
https://www.tscan.com |
| Zip |
2,451 |